NEWXXITEK^™ HVT+ND

Get a head start with early immunity

Details

NEWXXITEK™ HVT+ND is an HVT-vectored vaccine with a live Marek's disease serotype 3, containing a gene insert from a Newcastle disease virus (NCV).

NEWXXITEK™ HVT+ND is a HVT-vectored vaccine
Contains a F gene insert from the Texas velogenic strain of NDV
Developed using the same technology and expertise as VAXXITEK^® HVT+IBD

Key Advantages

HVT vector containing the F gene from the Texas velogenic strain of NDV
Same insertion site and promoter as VAXXITEK^® HVT+IBD
Clinical protection detected as early as two weeks after vaccination¹

Features & Benefits

Aids in the prevention of both Marek’s (equivalent to HVT) and Newcastle diseases
Convenient hatchery administration by subcutaneous or by in ovo vaccination
As safe as HVT vaccines with no live ND vaccine reaction
No interference with maternal antibodies
Seroconversion and clinical protection were detected as early as two weeks after NEWXXITEK™ HVT+ND vaccination¹
Clinical protection reached 100% at 28 days of age^2,3

Dosage & Administration

Packaged in 4 x 4,000 dose ampules in frozen presentation

Resources

Safety

Do not mix with other products, except as specified on the label
In case of human exposure, contact a physician
Administer only as recommended
Use entire contents when first opened
Do not vaccinate within 21 days before slaughter
Contains penicillin and streptomycin sulfate which are added as bacteriostatic agents
Contains Amphotericin B as a fungistatic agent
Inactivate unused contents before disposal

Safety Data Sheet

NEWXXITEK

References

¹Data on file at Boehringer Ingelheim.

²Data on file at Boehringer Ingelheim.

³Data on file at Boehringer Ingelheim.

Trademarks

US-POU-0058-2025

NEWCASTLE DISEASE CAN CAUSE INFLAMMATION OF THE EYELIDS OF HUMANS. EYE PROTECTION MUST BE WORN WHEN REHYDRATING AND ADMINISTERING THIS VACCINE. AVOID CONTAMINATING HANDS AND CLOTHING WITH THE VACCINE. HAND WASHING IS RECOMMENDED AFTER EXPOSURE TO THE PRODUCT.